A5053293171- Bone health and treatments
- Radiopharmaceutical Chemistry and Applications
- Bone health and osteoporosis research
- Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Bone and Joint Diseases
- Management of metastatic bone disease
- Bone Metabolism and Diseases
- Hip and Femur Fractures
- Estrogen and related hormone effects
- Parathyroid Disorders and Treatments
- Prostate Cancer Treatment and Research
- Growth Hormone and Insulin-like Growth Factors
- Cancer Treatment and Pharmacology
- Boron Compounds in Chemistry
- Vitamin D Research Studies
- HER2/EGFR in Cancer Research
- Bone fractures and treatments
- Sarcoidosis and Beryllium Toxicity Research
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Pain Management and Opioid Use
- Neuroendocrine Tumor Research Advances
- Pharmacological Effects and Toxicity Studies
- Neuropeptides and Animal Physiology
Centre Hospitalier Universitaire Brugmann
2016-2025
Université Libre de Bruxelles
2016-2025
Deleted Institution
2020
Institut Jules Bordet
2001-2011
Penn State Milton S. Hershey Medical Center
2011
Cancer Research UK
2011
Université Paris-Sud
2009
Seattle Cancer Care Alliance
2009
Institut Gustave Roussy
2009
Weatherford College
2008
Purpose Patients with bone metastases and elevated urinary N-telopeptide (uNTx), representing excessive resorption, are at increased risk for skeletal-related events (SREs), cancer progression, death. Osteoclast-mediated resorption is regulated by RANKL. We evaluated the effect of denosumab, a fully human monoclonal antibody against RANKL, in patients uNTx levels despite ongoing intravenous (IV) bisphosphonate (BP) therapy. Methods Eligible had histologically confirmed malignancy, ≥ 1...
Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or activator of NF-kappaB (RANKL). RANKL/RANK interaction important in terminal differentiation and activation osteoclasts. In binding to RANKL, blocks AMGN-0007 recombinant construct developed as potential therapeutic agent the treatment bone disease.A randomized, double-blind, double-dummy, active-controlled, single-dose, dose escalation study was conducted determine safety effect on resorption patients with multiple myeloma...
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in across tumour types and should part standard treatment.•Treatment-induced loss increases fracture risk may require use a bone-targeted agent addition to lifestyle modifications.•The bisphosphonate adjuvant therapies postmenopausal early breast reduces recurrence improves survival.
Teriparatide (rDNA origin) injection [recombinant human PTH (1–34)] stimulates bone formation, increases mineral density (BMD), and restores architecture integrity. In contrast, bisphosphonates reduce resorption increase BMD. We compared the effects of teriparatide alendronate sodium on BMD, nonvertebral fracture incidence, turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections 40 μg plus oral placebo (n = 73) or 10 mg 73). Median...
Although intravenous (i.v.) bisphosphonates are the standard of care for metastatic bone disease, they less than ideal many patients due to infusion-related adverse events (AEs), an increased risk renal toxicity and inconvenience regular hospital visits. The use oral bisphosphonate therapy is limited by concerns over efficacy gastrointestinal (GI) side effects. There remains a clinical need that offers equivalent i.v. bisphosphonates, good tolerability dosing convenience. Oral ibandronate,...
A RIA for PTH-related protein (PTHrP) is described, using a polyclonal goat antiserum against synthetic PTHrP-(1-40) and recombinant PTHrP-(1-84) as standard. The detection limit 2 pmol/L, intra- interassay coefficients of variation are 4.8% 13.6%, respectively. This assay does not detect PTH even at concentrations up to 2000 pmol/L. Cross-reactivity studies various PTHrP peptides localize the antibody-binding epitope between residues 20 29. Hypercalcemic patients with range solid tumors no...
The aim of this study was to determine whether Dickkopf-1 (Dkk-1) expression in breast cancer associated with bone metastases. We first analysed Dkk-1 by human cell lines that induce osteolytic or osteoblastic lesions animals. levels were then measured the marrow aspirates hind limbs from eight NMRI mice inoculated cells induced metastases and 11 age-matched non-inoculated control Finally, serum 17 women complete remission, 19 metastases, 16 at non-bone sites healthy women. Only animals...
Abstract BACKGROUND: In this study, the authors evaluated effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases. METHODS: The prevention pain, reduction interference daily life activities, proportion requiring strong opioid analgesics were assessed a randomized, double‐blind, double‐dummy phase 3 study comparing ZA for preventing skeletal‐related events 2046 who had Patients completed Brief Pain Inventory‐Short Form at baseline...